medcitynews.com Open in urlscan Pro
2606:4700:20::ac43:45a1  Public Scan

Submitted URL: http://go.pardot.com/e/710433/-aspen-neuroscience-nabs-147m-/f656c/514037293?h=OG6BSLgATNi9bn_zK_tGwcYPthLuGbxZ3oX9TU...
Effective URL: https://medcitynews.com/2022/05/aiming-to-treat-parkinsons-by-replacing-neurons-aspen-neuroscience-nabs-147m/
Submission: On May 11 via api from US — Scanned from DE

Form analysis 6 forms found in the DOM

GET https://medcitynews.com/

<form method="get" class="search" action="https://medcitynews.com/" role="search">
  <input type="text" class="field" name="s" value="" id="s" placeholder="Search …">
  <button type="submit"><i class="fa fa-search"></i></button>
</form>

GET https://medcitynews.com/

<form method="get" class="search" action="https://medcitynews.com/" role="search">
  <input type="text" class="field" name="s" value="" id="s" placeholder="Search …">
  <button type="submit"><i class="fa fa-search"></i></button>
</form>

POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983

<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983" enctype="multipart/form-data"
  id="hsForm_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" method="POST"
  class="hs-form stacked hs-form-private hsForm_a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983_96e7b0cf-0736-4e4c-8038-26e5fcb47966"
  data-form-id="a93d8b4e-029d-4de9-9599-c09510e52983" data-portal-id="2097126" target="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" data-reactid=".hbspt-forms-0">
  <div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-0.1:$0"><label id="label-email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" class=""
      placeholder="Enter your " for="email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" data-reactid=".hbspt-forms-0.1:$0.0"><span data-reactid=".hbspt-forms-0.1:$0.0.0"></span></label>
    <legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-0.1:$0.1"></legend>
    <div class="input" data-reactid=".hbspt-forms-0.1:$0.$email"><input id="email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" class="hs-input" type="email" name="email" required=""
        placeholder="Your email address*" value="" autocomplete="email" data-reactid=".hbspt-forms-0.1:$0.$email.0" inputmode="email"></div>
  </div><noscript data-reactid=".hbspt-forms-0.2"></noscript>
  <div class="hs_submit hs-submit" data-reactid=".hbspt-forms-0.5">
    <div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-0.5.0"></div>
    <div class="actions" data-reactid=".hbspt-forms-0.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-0.5.1.0"></div>
  </div><noscript data-reactid=".hbspt-forms-0.6"></noscript><input name="hs_context" type="hidden"
    value="{&quot;rumScriptExecuteTime&quot;:1824.2000000476837,&quot;rumServiceResponseTime&quot;:2616.899999856949,&quot;rumFormRenderTime&quot;:2.799999952316284,&quot;rumTotalRenderTime&quot;:4590,&quot;rumTotalRequestTime&quot;:380.59999990463257,&quot;embedAtTimestamp&quot;:&quot;1652271658913&quot;,&quot;formDefinitionUpdatedAt&quot;:&quot;1464813666301&quot;,&quot;pageUrl&quot;:&quot;https://medcitynews.com/2022/05/aiming-to-treat-parkinsons-by-replacing-neurons-aspen-neuroscience-nabs-147m/&quot;,&quot;pageTitle&quot;:&quot;Aiming to treat Parkinson’s by replacing neurons, Aspen Neuroscience nabs $147M - MedCity News&quot;,&quot;source&quot;:&quot;FormsNext-static-5.486&quot;,&quot;sourceName&quot;:&quot;FormsNext&quot;,&quot;sourceVersion&quot;:&quot;5.486&quot;,&quot;sourceVersionMajor&quot;:&quot;5&quot;,&quot;sourceVersionMinor&quot;:&quot;486&quot;,&quot;timestamp&quot;:1652271658915,&quot;userAgent&quot;:&quot;Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/101.0.4951.64 Safari/537.36&quot;,&quot;originalEmbedContext&quot;:{&quot;portalId&quot;:&quot;2097126&quot;,&quot;formId&quot;:&quot;a93d8b4e-029d-4de9-9599-c09510e52983&quot;,&quot;target&quot;:&quot;#newsletter-form-mobile-interstitial&quot;,&quot;formInstanceId&quot;:&quot;a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial&quot;},&quot;redirectUrl&quot;:&quot;http://medcitynews.com/youre-subscribed/&quot;,&quot;formInstanceId&quot;:&quot;a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial&quot;,&quot;renderedFieldsIds&quot;:[&quot;email&quot;],&quot;formTarget&quot;:&quot;#newsletter-form-mobile-interstitial&quot;,&quot;correlationId&quot;:&quot;48ad14e8-3138-4561-8131-4e22159cff7d&quot;,&quot;hutk&quot;:&quot;c78b65a24bb2cd9f73af5e62f9f1f3d1&quot;,&quot;captchaStatus&quot;:&quot;NOT_APPLICABLE&quot;}"
    data-reactid=".hbspt-forms-0.7"><iframe name="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" style="display:none;" data-reactid=".hbspt-forms-0.8"></iframe>
</form>

POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983

<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983" enctype="multipart/form-data" id="hsForm_a93d8b4e-029d-4de9-9599-c09510e52983"
  method="POST" class="hs-form stacked hs-form-private hsForm_a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983_3529fad8-71df-4113-88b2-3c77023d65c1"
  data-form-id="a93d8b4e-029d-4de9-9599-c09510e52983" data-portal-id="2097126" target="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983" data-reactid=".hbspt-forms-2">
  <div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-2.1:$0"><label id="label-email-a93d8b4e-029d-4de9-9599-c09510e52983" class="" placeholder="Enter your " for="email-a93d8b4e-029d-4de9-9599-c09510e52983"
      data-reactid=".hbspt-forms-2.1:$0.0"><span data-reactid=".hbspt-forms-2.1:$0.0.0"></span></label>
    <legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-2.1:$0.1"></legend>
    <div class="input" data-reactid=".hbspt-forms-2.1:$0.$email"><input id="email-a93d8b4e-029d-4de9-9599-c09510e52983" class="hs-input" type="email" name="email" required="" placeholder="Your email address*" value="" autocomplete="email"
        data-reactid=".hbspt-forms-2.1:$0.$email.0" inputmode="email"></div>
  </div><noscript data-reactid=".hbspt-forms-2.2"></noscript>
  <div class="hs_submit hs-submit" data-reactid=".hbspt-forms-2.5">
    <div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-2.5.0"></div>
    <div class="actions" data-reactid=".hbspt-forms-2.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-2.5.1.0"></div>
  </div><noscript data-reactid=".hbspt-forms-2.6"></noscript><input name="hs_context" type="hidden"
    value="{&quot;rumScriptExecuteTime&quot;:1824.2000000476837,&quot;rumServiceResponseTime&quot;:5000.5,&quot;rumFormRenderTime&quot;:1.6999998092651367,&quot;rumTotalRenderTime&quot;:5002.399999856949,&quot;rumTotalRequestTime&quot;:346.2000000476837,&quot;embedAtTimestamp&quot;:&quot;1652271661274&quot;,&quot;formDefinitionUpdatedAt&quot;:&quot;1464813666301&quot;,&quot;pageUrl&quot;:&quot;https://medcitynews.com/2022/05/aiming-to-treat-parkinsons-by-replacing-neurons-aspen-neuroscience-nabs-147m/&quot;,&quot;pageTitle&quot;:&quot;Aiming to treat Parkinson’s by replacing neurons, Aspen Neuroscience nabs $147M - MedCity News&quot;,&quot;source&quot;:&quot;FormsNext-static-5.486&quot;,&quot;sourceName&quot;:&quot;FormsNext&quot;,&quot;sourceVersion&quot;:&quot;5.486&quot;,&quot;sourceVersionMajor&quot;:&quot;5&quot;,&quot;sourceVersionMinor&quot;:&quot;486&quot;,&quot;timestamp&quot;:1652271661278,&quot;userAgent&quot;:&quot;Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/101.0.4951.64 Safari/537.36&quot;,&quot;originalEmbedContext&quot;:{&quot;portalId&quot;:&quot;2097126&quot;,&quot;formId&quot;:&quot;a93d8b4e-029d-4de9-9599-c09510e52983&quot;,&quot;target&quot;:&quot;#signup-main-hubspot&quot;,&quot;redirectUrl&quot;:&quot;http://medcitynews.com/youre-subscribed/&quot;},&quot;redirectUrl&quot;:&quot;http://medcitynews.com/youre-subscribed/&quot;,&quot;renderedFieldsIds&quot;:[&quot;email&quot;],&quot;formTarget&quot;:&quot;#signup-main-hubspot&quot;,&quot;correlationId&quot;:&quot;692c3a5f-56b4-4222-99f1-45c9e0dcd65d&quot;,&quot;hutk&quot;:&quot;c78b65a24bb2cd9f73af5e62f9f1f3d1&quot;,&quot;captchaStatus&quot;:&quot;NOT_APPLICABLE&quot;}"
    data-reactid=".hbspt-forms-2.7"><iframe name="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983" style="display:none;" data-reactid=".hbspt-forms-2.8"></iframe>
</form>

POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983

<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983" enctype="multipart/form-data"
  id="hsForm_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mc-startups" method="POST"
  class="hs-form stacked hs-form-private hsForm_a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983_9823de82-bd8d-4ce9-ae55-1411d71da443"
  data-form-id="a93d8b4e-029d-4de9-9599-c09510e52983" data-portal-id="2097126" target="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mc-startups" data-reactid=".hbspt-forms-1">
  <div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-1.1:$0"><label id="label-email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mc-startups" class="" placeholder="Enter your "
      for="email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mc-startups" data-reactid=".hbspt-forms-1.1:$0.0"><span data-reactid=".hbspt-forms-1.1:$0.0.0"></span></label>
    <legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-1.1:$0.1"></legend>
    <div class="input" data-reactid=".hbspt-forms-1.1:$0.$email"><input id="email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mc-startups" class="hs-input" type="email" name="email" required=""
        placeholder="Your email address*" value="" autocomplete="email" data-reactid=".hbspt-forms-1.1:$0.$email.0" inputmode="email"></div>
  </div><noscript data-reactid=".hbspt-forms-1.2"></noscript>
  <div class="hs_submit hs-submit" data-reactid=".hbspt-forms-1.5">
    <div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-1.5.0"></div>
    <div class="actions" data-reactid=".hbspt-forms-1.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-1.5.1.0"></div>
  </div><noscript data-reactid=".hbspt-forms-1.6"></noscript><input name="hs_context" type="hidden"
    value="{&quot;rumScriptExecuteTime&quot;:1824.2000000476837,&quot;rumServiceResponseTime&quot;:2707.899999856949,&quot;rumFormRenderTime&quot;:2.1000001430511475,&quot;rumTotalRenderTime&quot;:4615.700000047684,&quot;rumTotalRequestTime&quot;:318.69999980926514,&quot;embedAtTimestamp&quot;:&quot;1652271659001&quot;,&quot;formDefinitionUpdatedAt&quot;:&quot;1464813666301&quot;,&quot;pageUrl&quot;:&quot;https://medcitynews.com/2022/05/aiming-to-treat-parkinsons-by-replacing-neurons-aspen-neuroscience-nabs-147m/&quot;,&quot;pageTitle&quot;:&quot;Aiming to treat Parkinson’s by replacing neurons, Aspen Neuroscience nabs $147M - MedCity News&quot;,&quot;source&quot;:&quot;FormsNext-static-5.486&quot;,&quot;sourceName&quot;:&quot;FormsNext&quot;,&quot;sourceVersion&quot;:&quot;5.486&quot;,&quot;sourceVersionMajor&quot;:&quot;5&quot;,&quot;sourceVersionMinor&quot;:&quot;486&quot;,&quot;timestamp&quot;:1652271659004,&quot;userAgent&quot;:&quot;Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/101.0.4951.64 Safari/537.36&quot;,&quot;originalEmbedContext&quot;:{&quot;portalId&quot;:&quot;2097126&quot;,&quot;formId&quot;:&quot;a93d8b4e-029d-4de9-9599-c09510e52983&quot;,&quot;target&quot;:&quot;#newsletter-form-mc-startups&quot;,&quot;formInstanceId&quot;:&quot;a93d8b4e-029d-4de9-9599-c09510e52983-mc-startups&quot;},&quot;redirectUrl&quot;:&quot;http://medcitynews.com/youre-subscribed/&quot;,&quot;formInstanceId&quot;:&quot;a93d8b4e-029d-4de9-9599-c09510e52983-mc-startups&quot;,&quot;renderedFieldsIds&quot;:[&quot;email&quot;],&quot;formTarget&quot;:&quot;#newsletter-form-mc-startups&quot;,&quot;correlationId&quot;:&quot;150f5351-071c-498b-9129-8976332537ad&quot;,&quot;hutk&quot;:&quot;c78b65a24bb2cd9f73af5e62f9f1f3d1&quot;,&quot;captchaStatus&quot;:&quot;NOT_APPLICABLE&quot;}"
    data-reactid=".hbspt-forms-1.7"><iframe name="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mc-startups" style="display:none;" data-reactid=".hbspt-forms-1.8"></iframe>
</form>

POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/30083c7c-72db-412b-8a6e-e72e5b9308ce

<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/30083c7c-72db-412b-8a6e-e72e5b9308ce" enctype="multipart/form-data" id="hsForm_30083c7c-72db-412b-8a6e-e72e5b9308ce"
  method="POST" class="hs-form stacked hs-form-private hsForm_30083c7c-72db-412b-8a6e-e72e5b9308ce hs-form-30083c7c-72db-412b-8a6e-e72e5b9308ce hs-form-30083c7c-72db-412b-8a6e-e72e5b9308ce_f5e81ea3-de0a-4d07-84ab-5ca36ac8238c"
  data-form-id="30083c7c-72db-412b-8a6e-e72e5b9308ce" data-portal-id="2097126" target="target_iframe_30083c7c-72db-412b-8a6e-e72e5b9308ce" data-reactid=".hbspt-forms-3">
  <div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-3.1:$0"><label id="label-email-30083c7c-72db-412b-8a6e-e72e5b9308ce" class="" placeholder="Enter your " for="email-30083c7c-72db-412b-8a6e-e72e5b9308ce"
      data-reactid=".hbspt-forms-3.1:$0.0"><span data-reactid=".hbspt-forms-3.1:$0.0.0"></span></label>
    <legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-3.1:$0.1"></legend>
    <div class="input" data-reactid=".hbspt-forms-3.1:$0.$email"><input id="email-30083c7c-72db-412b-8a6e-e72e5b9308ce" class="hs-input" type="email" name="email" required="" placeholder="Your email address*" value="" autocomplete="email"
        data-reactid=".hbspt-forms-3.1:$0.$email.0" inputmode="email"></div>
  </div><noscript data-reactid=".hbspt-forms-3.2"></noscript>
  <div class="hs_submit hs-submit" data-reactid=".hbspt-forms-3.5">
    <div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-3.5.0"></div>
    <div class="actions" data-reactid=".hbspt-forms-3.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-3.5.1.0"></div>
  </div><noscript data-reactid=".hbspt-forms-3.6"></noscript><input name="hs_context" type="hidden"
    value="{&quot;rumScriptExecuteTime&quot;:1824.2000000476837,&quot;rumServiceResponseTime&quot;:5000.5,&quot;rumFormRenderTime&quot;:1.7999999523162842,&quot;rumTotalRenderTime&quot;:5016.399999856949,&quot;rumTotalRequestTime&quot;:347,&quot;embedAtTimestamp&quot;:&quot;1652271661302&quot;,&quot;formDefinitionUpdatedAt&quot;:&quot;1464813456785&quot;,&quot;pageUrl&quot;:&quot;https://medcitynews.com/2022/05/aiming-to-treat-parkinsons-by-replacing-neurons-aspen-neuroscience-nabs-147m/&quot;,&quot;pageTitle&quot;:&quot;Aiming to treat Parkinson’s by replacing neurons, Aspen Neuroscience nabs $147M - MedCity News&quot;,&quot;source&quot;:&quot;FormsNext-static-5.486&quot;,&quot;sourceName&quot;:&quot;FormsNext&quot;,&quot;sourceVersion&quot;:&quot;5.486&quot;,&quot;sourceVersionMajor&quot;:&quot;5&quot;,&quot;sourceVersionMinor&quot;:&quot;486&quot;,&quot;timestamp&quot;:1652271661305,&quot;userAgent&quot;:&quot;Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/101.0.4951.64 Safari/537.36&quot;,&quot;originalEmbedContext&quot;:{&quot;portalId&quot;:&quot;2097126&quot;,&quot;formId&quot;:&quot;30083c7c-72db-412b-8a6e-e72e5b9308ce&quot;,&quot;target&quot;:&quot;#interstitial_hubspot&quot;,&quot;redirectUrl&quot;:&quot;http://medcitynews.com/youre-subscribed/&quot;},&quot;redirectUrl&quot;:&quot;http://medcitynews.com/youre-subscribed/&quot;,&quot;renderedFieldsIds&quot;:[&quot;email&quot;],&quot;formTarget&quot;:&quot;#interstitial_hubspot&quot;,&quot;correlationId&quot;:&quot;c3df8821-d938-42aa-bba7-e2eb376a5098&quot;,&quot;hutk&quot;:&quot;c78b65a24bb2cd9f73af5e62f9f1f3d1&quot;,&quot;captchaStatus&quot;:&quot;NOT_APPLICABLE&quot;}"
    data-reactid=".hbspt-forms-3.7"><iframe name="target_iframe_30083c7c-72db-412b-8a6e-e72e5b9308ce" style="display:none;" data-reactid=".hbspt-forms-3.8"></iframe>
</form>

Text Content

Menu Search
 * Home
 * News
   * Health Tech
   * Biopharma
   * Devices & Diagnostics
   * Consumer / Employer
 * Contributors
   * MedCity Influencers
   * MedCitizens
 * Events
 * Jobs
 * Research
 * Newsletters

 * About Us
 * Advertising
 * Contact us

 * Send Tips
 * Advertising
 * About

 * Twitter
 * Facebook
 * RSS
 * Subscribe via email


X Close Signup Modal


MEDCITY >> INBOX

Get the latest industry news first when you subscribe to our daily newsletter.


We will never sell or share your information without your consent. See our
privacy policy.
 * Send Tips
 * Advertising
 * About

 * Twitter
 * Facebook
 * RSS
 * Subscribe via email


MEDCITY NEWS


OSMIND SCORES $40M INVESTMENT TO AID IN MENTAL HEALTH RESEARCH AND TREATMENT


PFIZER BUYS ITS WAY INTO MIGRAINE WITH $11.6B BIOHAVEN PHARMA ACQUISITION


A NEW KIND OF CMO: WHY YOUR COMPANY NEEDS A CHIEF MEDICAL OFFICER


TELADOC HEALTH CEO HIGHLIGHTS EVOLUTION OF TELEMEDICINE


BUILDING AND MOBILIZING YOUR COMMUNITY: ADDRESSING CHALLENGES IN ENGAGING
PATIENTS AND CAREGIVERS


VIRTUAL PHYSICAL THERAPY: A NEW HORIZON IN AMBULATORY ARTHROPLASTY RECOVERY


AIMING TO TREAT PARKINSON’S BY REPLACING NEURONS, ASPEN NEUROSCIENCE NABS $147M


INVEST PITCH PERFECT WINNER: MYBIOMETRY AIMS TO PREVENT ASTHMA ATTACKS LONG
BEFORE THEY HAPPEN


GENERAL CATALYST VC: THIS TYPE OF COLLABORATION WITH INTERMOUNTAIN IS WHY WE
WERE PUT ON EARTH


RECLAIM YOUR PRIVACY BY BRINGING STI TESTING INTO THE HOME


HOW CELL & GENE THERAPY STARTUPS CAN WARM UP TO INVESTORS IN THIS “BIOTECH
NUCLEAR WINTER”


THE NEW PARADIGM IN DRUG DEVELOPMENT: WHY PLATFORM TECHNOLOGY IS THE SOLUTION
PATIENTS AND PAYERS NEED


HOW IS AI MOVING THE NEEDLE IN THE PHARMACEUTICAL INDUSTRY?


OVERHAULING PRIOR AUTHORIZATION: HOW TO ACHIEVE BETTER OUTCOMES AT A LOWER COST


INVEST PITCH PERFECT WINNER: VINCERE HEALTH OFFERS UNDERSERVED PATIENTS A
HOLISTIC SOLUTION TO QUIT SMOKING


 * News
   * Health Tech
   * BioPharma
   * Devices & Diagnostics
   * Consumer / Employer
 * Contributors
   * MedCity Influencers
   * MedCitizens
 * Events
   * INVEST
   * INVEST PharmaTech
   * INVEST Digital Health
   * INVEST Population Health
 * Jobs
 * Research
 * Newsletters

Be Sure to Share Your Insights on Our Brief MedCity Audience Survey for a Chance
to Win a $250 AMEX Gift Card






BioPharma


AIMING TO TREAT PARKINSON’S BY REPLACING NEURONS, ASPEN NEUROSCIENCE NABS $147M


ASPEN NEUROSCIENCES IS DEVELOPING A CELL THERAPY THAT USES A PATIENT’S OWN STEM
CELLS TO DEVELOP A PERSONALIZED TREATMENT FOR PARKINSON’S DISEASE. THE APPROACH
IS SLIGHTLY DIFFERENT THAN THAT OF BAYER, WHOSE EXPERIMENTAL PARKINSON’S CELL
THERAPY IS MADE FROM STEM CELLS SOURCED FROM HEALTHY DONORS.

By Frank Vinluan

Post a comment / May 9, 2022 at 3:15 PM
1Shares

 

Parkinson’s disease patients lack sufficient amounts of a neurotransmitter that
plays a key role in the brain’s ability to control movement and motor
coordination. While drugs are available to address this deficiency, their
effectiveness wanes over time. Aspen Neurosciences aims to treat Parkinson’s
with a cell therapy. The biotech now has $147.5 million in new funding as it
prepares for a first test in humans that could show not only how its technology
works, but also whether it offers an edge over a Bayer cell therapy already in
the clinic.



Promoted




IMPORTANCE OF PATIENT CAPITAL IN LIFE SCIENCES

TSX Venture Exchange has a strong history of helping early stage health and life
sciences companies raise patient capital for research and development purposes.

Daniel Lubienietzky, Toronto Stock Exchange

The Series B round of financing announced Monday was co-led by GV, LYFE Capital,
and Revelation Partners.

The key brain chemical lacking in Parkinson’s patients is dopamine, which comes
from dopamine-producing neurons. According to Aspen, about half of these neurons
are lost before a patient’s Parkinson’s is diagnosed. The San Diego-based
biotech aims to use cell therapy to replace these neurons to restore the release
of dopamine and reconstruct neural networks.

Aspen makes its cell therapy, called ANPD001, from induced pluripotent stem
cells (iPSCs), which have the potential to become almost any type of human cell.
The biotech induces these cells to become dopamine-producing neurons. Just
before those cells mature, they are transplanted into the patient.

Aspen’s approach is a personalized one. The stem cells come from a skin biopsy
of the patient. Prior to transplantation of the autologous cell therapy back
into the patient, Aspen uses artificial intelligence to evaluate the potential
effectiveness of the cells. The company claims its process reduces the time and
cost of manufacturing a personalized cell therapy. Aspen also claims another
advantage: avoidance of immune system suppressing drugs. Because the therapy is
derived from a patient’s own cells, no immune-suppressing drugs are needed to
prevent the immune system from rejecting the cell therapy.

Promoted




HOW MEDTECH CAN BETTER INTEGRATE WITH HEALTHCARE WORKFLOWS THROUGH DIGITAL
SOLUTIONS

Healthcare industry is transitioning to value-based care models. That’s why the
medical device
industry's ability to continue the development of life-changing innovations will
rely on
demonstrating how new technology fits under this value-based paradigm. To build
future-ready solutions, it’s important to focus on choosing the right tools and
technology partners. The Innovaccer Health Cloud is well-positioned to do just
that!

Innovaccer's Rishav Krishna & Smriti Khera

Bayer is taking a similar approach to treating Parkinson’s. Like Aspen, the
pharmaceutical giant is developing a cell therapy that would be implanted into
the patient to restore dopamine production. However, Bayer’s cell therapy is
allogeneic—the iPSCs come from healthy donors. This off-the-shelf approach is
intended to offer its own advantages. Personalized cell therapies, such as CAR
T-therapies for cancer, require an expensive, multi-step manufacturing process
that takes a long time. But an off-the-shelf approach could result in therapies
that are readily available from a manufacturing process that is more scalable.

The experimental Bayer Parkinson’s cell therapy, DA01, comes from BlueRock
Therapeutics, a biotech joint venture that the pharmaceutical giant had formed
with Versant Ventures in 2016. In 2019, Bayer fully acquired BlueRock for $240
million up front and another $360 million tied to the achievement of milestones.

Bayer advanced the BlueRock Parkinson’s cell therapy into human testing last
summer, a Phase 1 clinical trial enrolling about a dozen patients. Those
patients will take medicines to partially suppress their immune system for one
year in order to prevent the body from rejecting the transplanted cells. Study
participants will then be monitored for two years to assess tolerability to the
treatment and the survival of the transplanted cells. Christian Rommel, head of
research and development at Bayer’s pharmaceuticals division, told MedCity News
in an interview during the J.P. Morgan Health Care Conference in January that
preliminary clinical data from the study could come within the next year.

According to Aspen, its lab and preclinical studies have demonstrated that its
approach can produce dopamine-releasing neurons. The company is preparing to
submit an investigational new drug application to the FDA. If the agency accepts
the filing, the company could proceed to patient screening and a planned Phase
1/2a clinical trial. Damien McDevitt, Aspen’s president and CEO, said in a
prepared statement that the Series B financing will also support development of
other therapies in the company’s pipeline, including autologous gene-corrected
cells and programs that explore the treatment of other neurological diseases.

Since its founding in 2018, Aspen says it has raised more than $220 million.
Other disclosed participants in the latest financing include new investors
Newton Investment Management, EDBI, LifeForce Capital, Medical Excellence
Capital Partners, Mirae Asset Capital, NS Investment. Earlier investors OrbiMed,
Arch Venture Partners, Frazier Life Sciences, Section32 and Alexandria Venture
Investments also participated in the Series B round.

Image: koto_feja, Getty Images



1Shares

TOPICS

Aspen Neuroscience, Bayer, cell therapy, Clinical Trials, deals, Investing,
Parkinson's Disease, San Diego, Startups




HEAR THE LATEST INDUSTRY NEWS FIRST. SIGN UP FOR OUR DAILY NEWSLETTER.


We will never sell or share your information without your consent. See our
privacy policy.

Promoted




BETTER PRIMARY CARE ISN’T ONLY GOOD FOR HEALTH—IT’S GOOD FOR BUSINESS

The rising cost of employer-sponsored healthcare makes it difficult for American
businesses to compete globally. That doesn’t have to be the reality. Learn how
one company changed its trajectory.

Tom Gentile, CEO of Spirit AeroSystems & Richard Gephardt, Co-founder of
SolidaritUS Health




GOT NEWS? SEND US A TIP




Promoted




THE RISE OF VIRTUAL-FIRST CARE: BRIDGING THE GAP BETWEEN ONLINE AND OFFLINE
PATIENT EXPERIENCES

In a webinar sponsored by Wheel, health tech executives will explore how
telehealth is increasingly becoming the first point of interaction between
patients and providers and the potential for hybrid care models to improve the
patient experience, health outcomes, and deliver cost savings.

Wheel and MedCity News


MEDCITY >> INBOX

Get the latest industry news first when you subscribe to our newsletter.


We will never sell or share your information without your consent. See our
privacy policy.

Promoted




IMPORTANCE OF PATIENT CAPITAL IN LIFE SCIENCES

TSX Venture Exchange has a strong history of helping early stage health and life
sciences companies raise patient capital for research and development purposes.

Daniel Lubienietzky, Toronto Stock Exchange



Promoted




HOW MEDTECH CAN BETTER INTEGRATE WITH HEALTHCARE WORKFLOWS THROUGH DIGITAL
SOLUTIONS

Healthcare industry is transitioning to value-based care models. That’s why the
medical device
industry's ability to continue the development of life-changing innovations will
rely on
demonstrating how new technology fits under this value-based paradigm. To build
future-ready solutions, it’s important to focus on choosing the right tools and
technology partners. The Innovaccer Health Cloud is well-positioned to do just
that!

Innovaccer's Rishav Krishna & Smriti Khera




×



HEAR THE LATEST INDUSTRY NEWS FIRST. SIGN UP FOR OUR DAILY NEWSLETTER.


No thanks
We will never sell or share your information without your consent. See our
privacy policy.
Advertise About Newsletter

Our Sites

 * 
 * 
 * 
 * 
 * 
 * 
 * 

© 2022 Breaking Media, Inc. All rights reserved. Registration or use of this
site constitutes acceptance of our Terms of Service and Privacy Policy.

Privacy Center | Do not sell my information

1Shares


WELCOME TO MEDCITYNEWS


MEDCITYNEWS ASKS FOR YOUR CONSENT TO USE YOUR PERSONAL DATA TO:

 * perm_identity
   Personalised ads and content, ad and content measurement, audience insights
   and product development
 * devices
   Store and/or access information on a device

expand_moreremove
Learn more
 * 
   How can I change my choice?
 * 
   What if I don't consent?
 * 
   How does legitimate interest work?
 * 
   Do I have to consent to everything?

Your personal data will be processed and information from your device (cookies,
unique identifiers, and other device data) may be stored by, accessed by and
shared with third party vendors, or used specifically by this site or app.

Some vendors may process your personal data on the basis of legitimate interest,
which you can object to by managing your options below. Look for a link at the
bottom of this page or in our privacy policy where you can withdraw consent.

Consent



Manage options

arrow_back

Data preferences


MANAGE YOUR DATA

You can choose how your personal data is used. Vendors want your permission to
do the following:

TCF vendors

help_outline


STORE AND/OR ACCESS INFORMATION ON A DEVICE

Cookies, device identifiers, or other information can be stored or accessed on
your device for the purposes presented to you. View details
Consent


SELECT BASIC ADS

Ads can be shown to you based on the content you’re viewing, the app you’re
using, your approximate location, or your device type. View details
ConsentLegitimate interesthelp_outline


CREATE A PERSONALISED ADS PROFILE

A profile can be built about you and your interests to show you personalised ads
that are relevant to you. View details
ConsentLegitimate interesthelp_outline


SELECT PERSONALISED ADS

Personalised ads can be shown to you based on a profile about you. View details
ConsentLegitimate interesthelp_outline


CREATE A PERSONALISED CONTENT PROFILE

A profile can be built about you and your interests to show you personalised
content that is relevant to you. View details
ConsentLegitimate interesthelp_outline


SELECT PERSONALISED CONTENT

Personalised content can be shown to you based on a profile about you. View
details
ConsentLegitimate interesthelp_outline


MEASURE AD PERFORMANCE

The performance and effectiveness of ads that you see or interact with can be
measured. View details
ConsentLegitimate interesthelp_outline


MEASURE CONTENT PERFORMANCE

The performance and effectiveness of content that you see or interact with can
be measured. View details
ConsentLegitimate interesthelp_outline


APPLY MARKET RESEARCH TO GENERATE AUDIENCE INSIGHTS

Market research can be used to learn more about the audiences who visit
sites/apps and view ads. View details
ConsentLegitimate interesthelp_outline


DEVELOP AND IMPROVE PRODUCTS

Your data can be used to improve existing systems and software, and to develop
new products View details
ConsentLegitimate interesthelp_outline


ENSURE SECURITY, PREVENT FRAUD, AND DEBUG

help_outline
Your data can be used to monitor for and prevent fraudulent activity, and ensure
systems and processes work properly and securely. View details


TECHNICALLY DELIVER ADS OR CONTENT

help_outline
Your device can receive and send information that allows you to see and interact
with ads and content. View details


MATCH AND COMBINE OFFLINE DATA SOURCES

help_outline
Data from offline data sources can be combined with your online activity in
support of one or more purposes View details


LINK DIFFERENT DEVICES

help_outline
Different devices can be determined as belonging to you or your household in
support of one or more of purposes. View details


RECEIVE AND USE AUTOMATICALLY-SENT DEVICE CHARACTERISTICS FOR IDENTIFICATION

help_outline
Your device might be distinguished from other devices based on information it
automatically sends, such as IP address or browser type. View details


USE PRECISE GEOLOCATION DATA

Your precise geolocation data can be used in support of one or more purposes.
This means your location can be accurate to within several meters. View details
Consent

Vendor preferences

Accept all



Confirm choices

arrow_back

Vendor preferences


CONFIRM OUR VENDORS

Vendors can use your data to provide services. Declining a vendor can stop them
from using the data you shared.

TCF vendors

help_outline


EXPONENTIAL INTERACTIVE, INC D/B/A VDX.TV

Cookie duration: 90 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ROQ.AD INC.

Cookie duration: 365 (days). Cookie duration resets each session.

View details | Privacy policylaunch
Consent


INDEX EXCHANGE, INC.

Cookie duration: 395 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


QUANTCAST INTERNATIONAL LIMITED

Cookie duration: 397 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


BEESWAXIO CORPORATION

Cookie duration: 395 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


SOVRN HOLDINGS INC

Cookie duration: 365 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ADIKTEEV

Doesn't use cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


RTB HOUSE S.A.

Cookie duration: 365 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


WIDESPACE AB

Cookie duration: 372 (days). Cookie duration resets each session.

View details | Storage details | Privacy policylaunch
Consent


THE TRADE DESK

Cookie duration: 365 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ADMETRICS GMBH

Doesn't use cookies.

View details | Privacy policylaunch
Consent


AMOBEE INC.

Cookie duration: 365 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


EPSILON

Cookie duration: 400 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


YAHOO EMEA LIMITED

Cookie duration: 365 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ADVENTORI SAS

Cookie duration: 90 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


TRIPLELIFT, INC.

Cookie duration: 90 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


XANDR, INC.

Cookie duration: 90 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


NEORY GMBH

Cookie duration: 90 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


UNRULY GROUP LLC

Cookie duration: 395 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


NEURAL.ONE

Cookie duration: 365 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ADITION TECHNOLOGIES GMBH

Cookie duration: 90 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ACTIVE AGENT (ADITION TECHNOLOGIES GMBH)

Cookie duration: 90 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


TABOOLA EUROPE LIMITED

Cookie duration: 366 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


SMART ADSERVER

Cookie duration: 396 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ADFORM

Cookie duration: 60 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


MAGNITE, INC.

Cookie duration: 365 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ADARA MEDIA UNLIMITED

Cookie duration: 730 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


SIFT MEDIA, INC

Doesn't use cookies.

View details | Privacy policylaunch
Consent


RAKUTEN MARKETING LLC

Cookie duration: 365 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


AVOCET SYSTEMS LIMITED

Cookie duration: 365 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


LIFESTREET CORPORATION

Doesn't use cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


SIZMEK BY AMAZON

Cookie duration: 396 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


OPENX

Cookie duration: 365 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


YIELDLAB AG

Cookie duration: 365 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ROKU ADVERTISING SERVICES

Cookie duration: 731 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


NANO INTERACTIVE GMBH

Cookie duration: 182 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


SIMPLIFI HOLDINGS INC

Cookie duration: 366 (days).

View details | Privacy policylaunch
Consent


PUBMATIC, INC.

Cookie duration: 90 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


COMSCORE B.V.

Cookie duration: 720 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


FLASHTALKING, INC.

Cookie duration: 730 (days).

View details | Privacy policylaunch
Consent


MEDIAMATH, INC.

Cookie duration: 393 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


SMAATO, INC.

Doesn't use cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


SEMASIO GMBH

Cookie duration: 366 (days). Cookie duration resets each session.

View details | Storage details | Privacy policylaunch
Consent


CRIMTAN HOLDINGS LIMITED

Cookie duration: 365 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


SCENE STEALER LIMITED

Cookie duration: 365 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


BETGENIUS LTD

Cookie duration: 365 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


TRESENSA TECHNOLOGIES, INC.

Doesn't use cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


CRITEO SA

Cookie duration: 390 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ADLOOX SA

Doesn't use cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


BLIS MEDIA LIMITED

Cookie duration: 400 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Storage details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


LOTAME SOLUTIONS, INC

Cookie duration: 274 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


LIVERAMP, INC.

Cookie duration: 365 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


GROUPM UK LIMITED

Cookie duration: 395 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


LOOPME LIMITED

Cookie duration: 365 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


DYNATA LLC

Cookie duration: 365 (days).

View details | Privacy policylaunch
Consent


FUSIO BY S4M

Cookie duration: 1 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


TEEMO SA

Cookie duration: 30 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


DOUBLEVERIFY INC.

Doesn't use cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


BIDSWITCH GMBH

Cookie duration: 365 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


IPONWEB GMBH

Cookie duration: 365 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


NEXTROLL, INC.

Cookie duration: 395 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


TEADS

Cookie duration: 365 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


STRÖER SSP GMBH (SSP)

Cookie duration: 365 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


STRÖER SSP GMBH (DSP)

Cookie duration: 90 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


PLATFORM161 B.V.

Cookie duration: 396 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ADACADO TECHNOLOGIES INC. (DBA ADACADO)

Cookie duration: 365 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


MEETRICS GMBH

Cookie duration: 365 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


SMADEX, S.L.U.

Cookie duration: 365 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


BOMBORA INC.

Cookie duration: 365 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


SPOTX, INC

Cookie duration: 365 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


EASYMEDIA GMBH

Cookie duration: 365 (days). Cookie duration resets each session.

View details | Privacy policylaunch
Consent


REMERGE GMBH

Doesn't use cookies.

View details | Privacy policylaunch
Consent


ADVANCED STORE GMBH

Cookie duration: 24856 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


MAGNITE CTV, INC.

Cookie duration: 366 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


DELTA PROJECTS AB

Cookie duration: 365 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


USEMAX ADVERTISEMENT (EMEGO GMBH)

Cookie duration: 365 (days). Cookie duration resets each session.

View details | Storage details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


EMETRIQ GMBH

Cookie duration: 365 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


PUBLICIS MEDIA GMBH

Cookie duration: 90 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
Consent


MCCANN DISCIPLINE LTD

Cookie duration: 14 (days).

View details | Privacy policylaunch
Consent


ONETAG LIMITED

Cookie duration: 741 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


CLOUD TECHNOLOGIES S.A.

Cookie duration: 365 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


SMARTOLOGY LIMITED

Doesn't use cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


IMPROVE DIGITAL

Cookie duration: 90 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ADOBE ADVERTISING CLOUD

Cookie duration: 365 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


BANNERFLOW AB

Cookie duration: 366 (days).

View details | Storage details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


TABMO SAS

Doesn't use cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


INTEGRAL AD SCIENCE, INC.

Doesn't use cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


WIZALY

Cookie duration: 365 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
Consent


WEBORAMA

Cookie duration: 393 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


JIVOX CORPORATION

Cookie duration: 90 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


MOBILE PROFESSIONALS BV / SAGE&#43;ARCHER BV

Doesn't use cookies.

View details | Privacy policylaunch
Consent


ON DEVICE RESEARCH LIMITED

Cookie duration: 30 (days).

View details | Privacy policylaunch
Consent


EXACTAG GMBH

Cookie duration: 180 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


CELTRA, INC.

Doesn't use cookies. Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


MAINADV SRL

Cookie duration: 1 (days). Cookie duration resets each session. Uses other forms
of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


GEMIUS SA

Cookie duration: 395 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
Consent


THE KANTAR GROUP LIMITED

Cookie duration: 914 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


IMPACT TECH INC.

Cookie duration: 720 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


NIELSEN MARKETING CLOUD

Cookie duration: 120 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


SOLOCAL

Cookie duration: 365 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


PIXALATE, INC.

Doesn't use cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ORACLE DATA CLOUD

Cookie duration: 180 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


NUMBERLY

Cookie duration: 396 (days).

View details | Privacy policylaunch
Consent


AUDIENCEPROJECT APS

Cookie duration: 365 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


EFFILIATION / EFFINITY

Cookie duration: 60 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ARRIVALIST CO

Cookie duration: 730 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


SEENTHIS AB

Doesn't use cookies.

View details | Privacy policylaunch


COMMANDERS ACT

Cookie duration: 365 (days). Uses other forms of storage.

View details | Privacy policylaunch
Consent


TRAVEL AUDIENCE GMBH

Cookie duration: 397 (days). Cookie duration resets each session.

View details | Storage details | Privacy policylaunch
Consent


HUMAN

Doesn't use cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ADLUDIO LTD.

Doesn't use cookies.

View details | Privacy policylaunch
Consent


NEODATA GROUP SRL

Cookie duration: 366 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


INNOVID INC.

Cookie duration: 92 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


TACTIC™ REAL-TIME MARKETING AS

Cookie duration: Uses session cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


NEUSTAR, INC., A TRANSUNION COMPANY

Cookie duration: 365 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


SUBLIMESKINZ - ADLEDGE

Doesn't use cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


SALESFORCE.COM, INC.

Cookie duration: 180 (days). Uses other forms of storage.

View details | Privacy policylaunch
Consent


VERVE GROUP EUROPE GMBH

Doesn't use cookies.

View details | Privacy policylaunch
Consent


KOCHAVA INC.

Doesn't use cookies.

View details | Privacy policylaunch
Consent


OTTO (GMBH &AMP; CO KG)

Cookie duration: 365 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ADOBE AUDIENCE MANAGER, ADOBE EXPERIENCE PLATFORM

Cookie duration: 180 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


LOCALSENSOR B.V.

Doesn't use cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ONLINE SOLUTION

Cookie duration: 365 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


RELAY42 NETHERLANDS B.V.

Cookie duration: 731 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


GP ONE GMBH

Cookie duration: Uses session cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


LIFTOFF MOBILE, INC.

Doesn't use cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


MINDTAKE RESEARCH GMBH

Cookie duration: 93 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


AAX LLC

Cookie duration: 2191 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


CINT AB

Cookie duration: 730 (days).

View details | Privacy policylaunch
Consent


GOOGLE ADVERTISING PRODUCTS

Cookie duration: 396 (days). Uses other forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


GFK SE

Cookie duration: 730 (days). Uses other forms of storage.

View details | Privacy policylaunch
Consent


REVJET

Cookie duration: 730 (days).

View details | Privacy policylaunch
Consent


DIGISEG APS

Doesn't use cookies.

View details | Privacy policylaunch
Consent


PROTECTED MEDIA LTD

Doesn't use cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


CLINCH LABS LTD

Cookie duration: 730 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


HEARTS &AMP; SCIENCE MÜNCHEN GMBH

Cookie duration: 60 (days). Cookie duration resets each session.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


AMAZON ADVERTISING

Cookie duration: 396 (days). Cookie duration resets each session. Uses other
forms of storage.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


MOLOCO, INC.

Cookie duration: Uses session cookies.

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


OBJECTIVE PARTNERS BV

Cookie duration: 90 (days). Cookie duration resets each session.

View details | Privacy policylaunch
Consent


EBAY INC

Cookie duration: 90 (days).

View details | Privacy policylaunch
ConsentLegitimate interesthelp_outline

General vendors

help_outline


GSKINNER

Privacy policylaunch
Consent


AKAMAI

Privacy policylaunch
Consent


FACEBOOK

Privacy policylaunch
Consent


AUNICA

Privacy policylaunch
Consent


BOOKING.COM

Privacy policylaunch
Consent


C3 METRICS

Privacy policylaunch
Consent


IBM

Privacy policylaunch
Consent


ADTRIBA

Privacy policylaunch
Consent


PULSEPOINT

Privacy policylaunch
Consent


DEMANDBASE

Privacy policylaunch
Consent


EVIDON

Privacy policylaunch
Consent


CUBED

Privacy policylaunch
Consent


HURRA.COM

Privacy policylaunch
Consent


OPTOMATON

Privacy policylaunch
Consent


INTELLIAD

Privacy policylaunch
Consent


ANALIGHTS

Privacy policylaunch
Consent


DSTILLERY

Privacy policylaunch
Consent


DMA INSTITUTE

Privacy policylaunch
Consent


ZMS

Privacy policylaunch
Consent


DENTSU AEGIS NETWORK

Privacy policylaunch
Consent


IGNITION ONE

Privacy policylaunch
Consent


OMNICOM MEDIA GROUP

Privacy policylaunch
Consent


RESONATE

Privacy policylaunch
Consent


CENTRO

Privacy policylaunch
Consent


SOJERN

Privacy policylaunch
Consent


HAENSEL AMS

Privacy policylaunch
Consent


BDSK HANDELS GMBH & CO. KG

Privacy policylaunch
Consent


VIDEOLOGY

Privacy policylaunch
Consent


TRADEDOUBLER AB

Privacy policylaunch
Consent


TRUSTARC

Privacy policylaunch
Consent


TRUEFFECT

Privacy policylaunch
Consent


MARKETING SCIENCE CONSULTING GROUP, INC.

Privacy policylaunch
Consent


DENTSU

Privacy policylaunch
Consent


ESSENS

Privacy policylaunch
Consent


TRAVEL DATA COLLECTIVE

Privacy policylaunch
Consent


ADVOLUTION.CONTROL

Privacy policylaunch
Consent


VIMEO

Privacy policylaunch
Consent


ENSIGHTEN

Privacy policylaunch
Consent


ADMAXIM

Privacy policylaunch
Consent


BATCH MEDIA

Privacy policylaunch
Consent


VODAFONE GMBH

Privacy policylaunch
Consent


NETQUEST

Privacy policylaunch
Consent


MANAGE.COM

Privacy policylaunch
Consent


CLOUDFLARE

Privacy policylaunch
Consent


SCOOTA

Privacy policylaunch
Consent


HAVAS MEDIA FRANCE - DBI

Privacy policylaunch
Consent


NETFLIX

Privacy policylaunch
Consent


MACROMILL GROUP

Privacy policylaunch
Consent


EBUILDERS

Privacy policylaunch
Consent


APPLOVIN CORP.

Privacy policylaunch
Consent


FRACTIONAL MEDIA

Privacy policylaunch
Consent


RACKSPACE

Privacy policylaunch
Consent


MSI-ACI

Privacy policylaunch
Consent


NAVEGG

Privacy policylaunch
Consent


ADMEDO

Privacy policylaunch
Consent


MOBITRANS

Privacy policylaunch
Consent


ADEX

Privacy policylaunch
Consent


SPOTAD

Privacy policylaunch
Consent


AARKI

Privacy policylaunch
Consent


SFR

Privacy policylaunch
Consent


CABLATO

Privacy policylaunch
Consent


WAYSTACK

Privacy policylaunch
Consent

Accept all



Confirm choices

Close

Share this Article

Friend's Email Address

Your Name

Your Email Address

Comments

Send Email

Email sent!

×